Reference number : GC-2017-Q4-00920, amendment number : , agreement type : G, recipient legal name : Kieffer, Timothy (The University of British Columbia), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : The goal of this project is to develop an implantable bioprinted 3D tissue containing stem cell-derived beta_x000D_
cells within a network of tubes, that demonstrates high cell viability and appropriate insulin-releasing_x000D_
capability. The project represents a new collaboration between two leading Canadian technology developers:_x000D_
Aspect, a Vancouver-based company focused on the development and commercialization of 3D bioprinting_x000D_
technology, and the University of BC laboratory of Dr. Timothy Kieffer, where protocols have been developed_x000D_
for the production of insulin producing cells from human embryonic stem (ES) cells. The Kieffer lab will_x000D_
provide Aspect with human ES cells that have been differentiated into pancreatic progenitor cells or beyond_x000D_
(towards mature beta cells) where they will be bioprinted by Aspect into living biocompatible 3D structures_x000D_
using Aspect's unique alginate/collagen bioink. The bioprinted tissues will then be rigorously characterized for_x000D_
cell viability, maturation, and insulin production in response to nutrients, both in vitro and following implant_x000D_
into mice. Subsequent studies will explore strategies to improve graft vascularization while also assessing the_x000D_
immunoprotective aspects of the bioprinted tissue. The project will provide an excellent training opportunity_x000D_
for students in cutting edge biomedical engineering at the interface of academia and industry, and could lead to_x000D_
substantial investments in follow-up research and development., program purpose french : The goal of this project is to develop an implantable bioprinted 3D tissue containing stem cell-derived beta_x000D_
cells within a network of tubes, that demonstrates high cell viability and appropriate insulin-releasing_x000D_
capability. The project represents a new collaboration between two leading Canadian technology developers:_x000D_
Aspect, a Vancouver-based company focused on the development and commercialization of 3D bioprinting_x000D_
technology, and the University of BC laboratory of Dr. Timothy Kieffer, where protocols have been developed_x000D_
for the production of insulin producing cells from human embryonic stem (ES) cells. The Kieffer lab will_x000D_
provide Aspect with human ES cells that have been differentiated into pancreatic progenitor cells or beyond_x000D_
(towards mature beta cells) where they will be bioprinted by Aspect into living biocompatible 3D structures_x000D_
using Aspect's unique alginate/collagen bioink. The bioprinted tissues will then be rigorously characterized for_x000D_
cell viability, maturation, and insulin production in response to nutrients, both in vitro and following implant_x000D_
into mice. Subsequent studies will explore strategies to improve graft vascularization while also assessing the_x000D_
immunoprotective aspects of the bioprinted tissue. The project will provide an excellent training opportunity_x000D_
for students in cutting edge biomedical engineering at the interface of academia and industry, and could lead to_x000D_
substantial investments in follow-up research and development., agreement title english : Bioprinting novel 3D tissues with human ES-derived pancreatic beta cells to regulate blood glucose via the appropriate release of insulin, agreement title french : Bioprinting novel 3D tissues with human ES-derived pancreatic beta cells to regulate blood glucose via the appropriate release of insulin, agreement number : EGP, agreement value : 25000.0, agreement start date : 2018-03-07, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada